Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 09, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 300,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,553.09 pence per share.
- Treasury Shares Held: 160,714,678 shares (post-transaction).
- Shares in Issue: 5,819,711,187 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on May 09, 2006, pursuant to shareholder authority granted at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 300,000 share repurchase against the stated price of 1,553.09 pence.
- Confirm the updated total share count (5,819,711,187 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to confirm the scope of the buyback authority utilized.